Filing Flows › Comparisons › BMRN vs AMRX
BioMarin Pharmaceutical vs Amneal Pharmaceuticals: BMRN and AMRX compared
BioMarin Pharmaceutical is the larger company: $1.0B of revenue in its latest quarter (Q3 2026) against $863M for Amneal Pharmaceuticals (Q3 2026). BioMarin Pharmaceutical is growing faster (+32% against +10% a year earlier). Amneal Pharmaceuticals is more profitable, with an operating margin of 11.1% against -8.0%.
Where the money goes: BMRN and AMRX
BioMarin Pharmaceutical (BMRN) · Q3 2026
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Amneal Pharmaceuticals (AMRX) · Q3 2026
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
| BioMarin Pharmaceutical (BMRN) | Amneal Pharmaceuticals (AMRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.0B | $863M |
| Revenue growth, Y/Y | +32% | +10% |
| Gross margin | — | 38.7% |
| Operating margin | -8.0% | 11.1% |
| Net earnings | −$123M | $12.3M |
| Net margin | -12.0% | 1.4% |
| Operating cash flow | $188M | $98.3M |
| Free cash flow | $160M | $66.5M |
| Market value | $10.8B | $6.6B |
| P/E | — | 30.7× |
| Analysts’ mean target | $90.78 | $23.86 |
Where the revenue comes from
BioMarin Pharmaceutical
- Net product revenues: $1.0B (99%)
- Royalty and other revenues: $11.6M (1%)
Questions
Which is bigger, BioMarin Pharmaceutical or Amneal Pharmaceuticals?
BioMarin Pharmaceutical is the larger company: $1.0B of revenue in its latest quarter (Q3 2026) against $863M for Amneal Pharmaceuticals (Q3 2026).
Is BioMarin Pharmaceutical or Amneal Pharmaceuticals growing faster?
BioMarin Pharmaceutical is growing faster (+32% against +10% a year earlier).
Which is more profitable, BioMarin Pharmaceutical or Amneal Pharmaceuticals?
Amneal Pharmaceuticals is more profitable, with an operating margin of 11.1% against -8.0%.
More: BioMarin Pharmaceutical earnings · how BioMarin Pharmaceutical makes money · Amneal Pharmaceuticals earnings · how Amneal Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 8-K filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.